Biologic Agents in the Treatment of Multicentric Castleman Disease

about

Biologic Agents in the Treatment of Multicentric Castleman Disease

Item

http://www.wikidata.org/entity/Q59137206

description

scientific article published on 01 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Biologic Agents in the Treatment of Multicentric Castleman Disease

@en

Biologic Agents in the Treatment of Multicentric Castleman Disease

@nl

type

Item

label

Biologic Agents in the Treatment of Multicentric Castleman Disease

@en

Biologic Agents in the Treatment of Multicentric Castleman Disease

@nl

prefLabel

Biologic Agents in the Treatment of Multicentric Castleman Disease

@en

Biologic Agents in the Treatment of Multicentric Castleman Disease

@nl

P1476

Biologic Agents in the Treatment of Multicentric Castleman Disease

@en

P2093

David R Lawrence

http://www.w3.org/2001/XMLSchema#string

Davide Patrini

http://www.w3.org/2001/XMLSchema#string

Konstantinos Kapriniotis

http://www.w3.org/2001/XMLSchema#string

Nikolaos Panagiotopoulos

http://www.w3.org/2001/XMLSchema#string

Savvas Lampridis

http://www.w3.org/2001/XMLSchema#string

Sofoklis Mitsos

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

Case records of the Massachusetts General Hospital: Case No. 40231.

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

P304

220-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5152/TURKTHORACJ.2018.18066

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Savvas Lampridis

Sofoklis Mitsos

Davide Patrini

Nikolaos Panagiotopoulos

Konstantinos Kapriniotis

David R Lawrence

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30455994

http://www.w3.org/2001/XMLSchema#string

P932

6196909

http://www.w3.org/2001/XMLSchema#string